50 results about "Clinical performance" patented technology

A method of predicting clinical performance of an ophthalmic optical correction using simulation by imaging a series of objects of different sizes by each of a plurality of eye optical systems, each of the eye optical systems including the ophthalmic optical correction, the method providing an output value representing the resolution and contrast performance of the optical design at that vergence for the eye optical systems.

An apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses is disclosed. Ophthalmic lenses may include, for example, contacts, glasses or intraocular lenses (IOLs). The apparatus, system and method may include a design tool for designing a lens for implantation in an eye having a plurality of characteristics, a simulator for simulating performance of the lens in at least one modeled eye having the plurality of characteristics, at least one input for receiving clinical performance of the lens in the eye having the plurality of characteristics, a comparator for comparing outcomes of the clinical performance and the simulated performance, and an optimizer for optimizing a subsequent one of the outcome of the clinical performance responsive to modification of the lens in accordance with modification to the simulated performance.

Embodiments of clinical support systems and methods are disclosed. In one embodiment, methods for clinical performance measurement are disclosed comprising defining a range of acceptable treatment variable values for a treatment variable of a subject, performing a selected intervention, determining an affected treatment variable value and determining a selection performance measure by comparing the affected treatment variable value to the acceptable treatment variable values. In one embodiment, methods for clinical decision training are disclosed comprising defining a treatment variable of a simulated subject, selecting an intervention on the treatment variable, modeling the selected intervention and presenting a visual representation of the selected intervention. In one embodiment, methods for clinical decision support are disclosed comprising defining a treatment variable of a subject, presenting a decision support variable as clinical decision support, performing a selected intervention and determining an affected treatment variable value.

Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.

Multi-metric surgery simulator devices, systems, and methods, involving at least one sensor configured to collect surgical training performance data relevant to at least one surgical task, the at least one sensor configured to operate with a surgical navigation system comprising a processor, the processor configurable, by way of a set of executable instructions storable in relation to a non-transitory medium, to perform at least one of analyze collected data, transform the collected data, and provide feedback in relation thereto; and at least one surgery simulator apparatus operatively coupled with the at least one sensor, the at least one surgery simulator apparatus configured to operate with a tracking system, whereby collected data is obtainable and clinical performance in relation to the at least one surgical task is quantitatively evaluable and progressively improvable.

Certain embodiments provide systems and methods for health information exchange. Certain embodiments provide a health information exchange system. The system includes an interface accommodating a plurality of data sources transmitting data for storage at the health information exchange system. The system also includes a shared data repository configured to aggregate and store patient-related data from the plurality of data sources. The shared data repository is accessible to a community of users via the health information exchange system. The system further includes a query engine for querying the shared data repository to retrieve a subset of patient-related data. Additionally, the system includes a Web-based portal providing an authorized user access to the subset of patient-related data for at least one of patient care and clinical performance.

Clinical performance of currently available human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equivalents in vivo. Living skin equivalents were constructed by sequentially seeding the apical and basal surfaces of acellular dermis with cultured human keratinocytes and Bcl-2 transduced HUVEC or umbilical cord cells sequentially. After orthotopic implantation of grafts comprising cultured human keratinocytes and Bcl-2 transduced HUVEC cells onto mice, the grafts displayed both a differentiated human epidermis and perfusion through the HUVEC-lined microvessels. These vessels, which showed evidence of progressive maturation, accelerated the rate of graft vascularization. Successful transplantation of such vascularized human skin equivalents should enhance clinical utility, especially in recipients with impaired angiogenesis.

A method of calculating clinical performance of an ophthalmic optical correction using simulation by imaging a series of objects of different sizes by each of a plurality of eye optical systems, each of the eye optical systems including the ophthalmic optical correction, the method comprising A.) at an object distance, calculating a set of indicia of image quality, each indicium of the set of indicia corresponding to an object in the series of objects when it is imaged by a given one of the plurality of eye optical systems, B.) at the object distance, comparing the set of indicia to a threshold to determine a just-discernable object size for the given one of the plurality of eye optical systems, and C.) repeating steps A and B for each eye optical system in the plurality of eye optical systems.

The invention discloses a photoacoustic imaging device free of limitation of ultrasonic transducer frequency bands and a detection method of the photoacoustic imaging device. The photoacoustic imaging device comprises a photoacoustic excitation assembly, a photoacoustic signal detection assembly, a photoacoustic signal collection / processing assembly and a sample platform, the photoacoustic excitation assembly, the photoacoustic signal detection assembly and the photoacoustic signal collection / processing assembly are sequentially connected, the photoacoustic excitation assembly and the photoacoustic signal collection / processing assembly are connected, and the photoacoustic signal detection assembly is connected with the sample platform. According to the photoacoustic imaging device, pulse lasers are used for radiating a biological sample to generate photoacoustic signals, continuous lasers with narrow line width are focused on the surface of the sample, vibration speeds of the surface of the sample are detected to achieve the purpose of detecting the photoacoustic signals, the defect of bandwidth limitation of the transducer is overcome, and the defects that high frequency photoacoustic signals are sharply attenuated in biological tissues and can not be detected are overcome; detection portions are not required to be subjected to any processing, requirements for imaging environment conditions are low, and large pushing functions on clinical performances of photoacoustic technology are achieved.

A method and system for providing performance evaluations, on a timely basis, to students or trainees, is provided. In one contemplated embodiment, the inventive method and system are used in health care training programs to form an information feedback loop whereby clinical and simulated clinical performance evaluations are inputted, or gathered and stored, and then made available to the health care practitioner and to his / her educator(s) throughout the health care training program thereby increasing the effectiveness of the training program by allowing the program to be continuously tailored to address the needs of the health care practitioner.

A method for calculating and reporting image quality properties of an image acquisition device after a subject or object has been scanned consists of a scan quality monitoring system with automated software for receiving scans and radiation dose data from scanners and automated algorithms for analyzing image quality metrics and radiation dose tradeoffs. Image quality assessment methods include algorithms for measuring fundamental imaging characteristics, level and type of image artifacts, and comparisons against large databases of historical data for the scanner and protocols. Image quality reports are further customized to report on expected clinical performance of image detection or measurement tasks.

The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

The present invention provides analytic utilities to an employer or health plan administrator as the financial underwriter of medical, prescription drug, and disability income protection for employees. It is specifically designed to integrate the use of evidence based clinical performance data and prescription drug possession ratios as part of a network optimization application; provide insights into disease progression and population migration over multiple time periods; calculate the impact on productivity as result of risk levels and health conditions; and make available advanced financial modeling capabilities utilizing econometric models and simulation.

The present invention is directed to a miniaturized biosensor and nanotechnology which is embedded in a variety of medical devices which can be used for real-time device location tracking and analysis, for the purpose of optimizing device positioning both at the time of initial placement and throughout its clinical use (i.e., device continuum). The continuously acquired device-specific standardized data is then transmitted through wireless communication networks to provide continuous feedback and alerts to authorized clinical providers as to device positioning, clinical performance, and presence of pathology.

The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

A method and system for providing performance evaluations, on a timely basis, to students or trainees, is provided. In one contemplated embodiment, the inventive method and system are used in health care training programs to form an information feedback loop whereby clinical and simulated clinical performance evaluations are inputted, or gathered and stored, and then made available to the health care practitioner and to his / her educator(s) throughout the health care training program thereby increasing the effectiveness of the training program by allowing the program to be continuously tailored to address the needs of the health care practitioner.

The invention provides a traditional Chinese medicine preparation for treating a phlegm-heat excessive accumulation type chronic cough. The traditional Chinese medicine is prepared from rhizome of ephedra sinica, apricot kernels, raw gypsum, radix glycyrrhizae, caulis bambusae in taeniam, fruits of immature citron, rhizoma pinellinae praeparata, fructus gardenia, Scutellaria baicalensis, Platycodon grandiflorum, perillaseeds, the root bark of white mulberry, cortex lycii radicis, polished round-grained rice, semen lepidii, rhizoma phragmitis, tuber of dwarf lilyturf, thunberg fritillary bulb, poria cocos, trichosanthes kirilowii maxim, common hogfennel roots, cynanchum glaucescens, radix stemonae, cordate houttuynia, tangerine peels, honeysuckle and indigo naturalis. Under the guidance of the theory of traditional Chinese medicine, on the basis of a large amount of clinical observation, the pattern of syndrome, clinical performance, treatment prognosis and the like are comprehensively analyzed, prescription medication is achieved, the effects of cough relieving, asthma relieving and phlegm dispersing are achieved, and it proves that the traditional Chinese medicine preparation has the effect of treating the phlegm-heat excessive accumulation type chronic cough through animal experimental verification and traditional Chinese medicine safety evaluation.

The invention relates to a model of a rat suffered from heat blood stasis syndrome, which makes the induction by continuous LPS abdominal cavity injection of the rat. The model is characterized in that the continuous LPS abdominal cavity injection is made twice a week, namely one injection at intervals of three days or four days. The rat model makes the induction by continuous LPS abdominal cavity injection of the rat, so that the established heat blood stasis syndrome animal model is good in stability and long in survival time, and the simulated symptoms are nearly line with the actual clinical performance and the objective detection indexes, not only the model is more similar to the presentation of the blood stasis syndrome in extrinsic feature, but also the mode can be judged by utilizing a plurality of more detailed biological indicators.

Tumor Necrosis Factor-α (TNFα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of TNF production is implicated in a variety of human diseases including Alzheimer's disease, cancer, major depression, and inflammatory bowel disease. These disorders are treated with a TNFα inhibitor. Embodiments herein provide methods of preventing and / or treating acute and chronic inflammation, and autoimmune diseases by administering a prophylactic and / or therapeutic formulation containing an antibody fragment (Fab or F(ab′)2) of adalimumab modified by conjugation of natural amino acids such as proline, alanine and / or serine (PA / S) by PASylation®, and / or unnatural amino acids such as cysteine and other derivatives, thereby creating a polypeptide possessing none of the processing, preparation, formulation, cost, clinical performance, and other long-term issues of administering PEGylated drugs.

Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.

The invention provides a system for realizing diagnosis logic based on the design of a structured report subtemplate, which comprises a feature definition module for configuring a CDE set corresponding to feature description of each diagnosis type, the CDE set comprising CDE of a part / tissue of a disease, CDE of an imaging representation feature and CDE of a clinical representation feature, wherein each CDE is composed of at least one sub CDE; a diagnosis type sequencing module, wherein when a doctor fills in the CDE set of the diagnosis type corresponding to the core focus, the diagnosis typesequencing module performs priority sequencing on the diagnosis type associated with the CDE set according to a preset rule; a CDE logic recommendation module which is used for automatically loadingthe next sub-CDE for the doctor to fill every time the doctor completes the sub-CDE under one sorted diagnosis type until the last CDE set is filled up; and a structured report generation module whichoutputs a diagnosis conclusion. The invention also discloses a method for realizing diagnosis logic based on the design of the structured report subtemplate. According to the invention, the difficulty of doctor image diagnosis can be reduced and the working efficiency of doctors is improved.

Provided herein are compositions, comprising hyaluronic acid in three different forms. The compositions are in a form of an essentially homogeneous gel with improved rheological properties enabling improved clinical performance.

The invention belongs to the technical field of bioscience, and particularly relates to a primates Parkinson's disease (PD) model behavior assessment optimal method. The method comprises the steps of establishing a rhesus monkey PD animal model; injecting MPTP into muscle of a rhesus monkey once a day till typical and stable PD clinical symptoms appear, wherein dosage is 0.2-0.5 mg / kg according to individual sensitivity difference; conducting behavior assessment on the rhesus monkey at two fixed time periods each day while MPTP injection is conducted, and taking the average score of one week as the final score of the week. A set of complete primates PD model behavior assessment method is provided and can be used for new drug efficacy assessment and horizontal and vertical comparative study of different new drugs. The assessment method absorbs the advantages and discards the disadvantages of different rating scales, and can reflect individual clinical difference comprehensively and accurately based on practical experience and clinical performance characteristics of rhesus monkeys, and individual clinical difference includes individual sensitivity difference, disease severity difference, disease sequence difference and individual PD feature difference.

The present invention relates to a web-based platform to track medical clinical assignments and to link embedded evaluation instruments to procedure type, for the optimization and improvement of medical clinical education and performance for healthcare professions, and in particular for graduate residents, such as surgical residents. This model is the basis for the platform for physician scoring and profiling to determine physician educational and performance competency with a selected medical procedure. The invention provides methods and systems for improving or optimizing performance tracking of a medical professional.

The invention relates to the technical field of medical training, and particularly discloses a medical dummy training system, which comprises a data processing server, and a signal simulation module, a human body bionic module, an illness state diagnosis and treatment module, a diagnosis result statistics module, a medical database and a user management module which are electrically connected with the data processing server, clinical phenomena and treatment data of different illness states are stored in the medical database, the signal simulation module sends out clinical manifestation data of the illness states, and the human body bionic module simulates clinical manifestations. Different users are distinguished through the user management module, diagnosis results and treatment measures are made through the illness state diagnosis and treatment module, and the diagnosis result statistics module counts the diagnosis and treatment accuracy. According to the medical dummy training system provided by the invention, different illness conditions can be simulated, so that trainees can be familiar with and perform practice, the proficiency of diagnosis and treatment can be effectively improved, the unfamiliar degree of the trainees to the illness conditions is reduced, and the training efficiency and quality are improved.

The invention provides an intelligent decision analysis system and method for clinical diagnosis and treatment. A clinical diagnosis and treatment knowledge base module stores various clinical diagnosis and treatment knowledge in a unified representation form; wherein the clinical evaluation module takes the clinical manifestation of the new patient as input, and executes a rule reasoning mechanism to output an evaluation result of the new patient; then the clinical treatment scheme decision module analyzes the clinical manifestation of the new patient and the similarity between clinical evaluation and historical cases by utilizing clinical diagnosis and treatment guidelines and case literature report knowledge in the clinical diagnosis and treatment knowledge base module and combining the evaluation result output by the clinical evaluation module, and finds out a diagnosis and treatment case most similar to the new patient. and according to the treatment scheme of the most similar diagnosis and treatment case, an example is provided for treatment of a new patient. According to the method, a large amount of differentiated data in the specific disease diagnosis and treatment field can be effectively classified and sorted, so that a more efficient and reliable disease diagnosis and treatment result is provided for a patient in combination with doctor expert experience and an intelligent auxiliary decision making system.

A method for evaluating emergency medical service according to embodiments of the present invention includes receiving emergency medical service data from a database, filtering the emergency medical service data based on a selection criteria to form a filtered emergency medical service data set, determining a first score from the filtered emergency medical service data set, where the first score indicates objective clinical performance quality for the filtered emergency medical service data set, determining a second score from the filtered emergency medical service data set, where the second score indicates objective operational performance quality for the filtered emergency medical service data set, merging the first score and the second score to form a composite score; and visually displaying the composite score to a user.

The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.